Risk of Contrast-Induced Nephropathy in CKD Stage 3 or 4

Quantifying the Risk by CKD Stage

• Patients with CKD stage 3 have a CIN incidence of approximately 13.6% even with prophylactic intravenous hydration 1
• The risk is significantly elevated compared to patients with normal renal function (2.7%) 1
• CKD stage 4 represents the highest risk category for CIN, with rates approaching 13.6% or higher depending on additional risk factors 1, 2
• In cancer patients with pre-existing kidney disease, CIN prevalence reaches 9%, with 50% experiencing irreversible kidney injury 1

Critical Risk Modifiers That Increase CIN Percentage

• Higher contrast volumes directly correlate with increased CIN risk 4, 5
• Elderly age (>70 years) is an independent risk factor 2
• Concomitant nephrotoxic medications (NSAIDs, aminoglycosides) increase risk 2

Clinical Outcomes and Mortality Impact

• Persistent worsening of renal function (>10% decrease from baseline) after contrast exposure is associated with a 7.3-fold higher mortality risk 3
• In NSTE-ACS patients with CKD, mortality increases progressively with declining eGFR, with adjusted HR of 1.70 for eGFR <45 mL/min/1.73m² 4, 5

Important Caveats

• Recent propensity score-matched analyses encompassing over 60,000 patients, including those with cancer, show no significantly enhanced AKI risk with contrast-enhanced versus unenhanced CT 1
• The American College of Cardiology states that the risk of contrast-induced AKI should not be a reason to withhold contrast in most patients with CKD stage 4 when clinically needed 6